Key clinical point: Health-related quality of life (HRQoL) improved in patients on twice-daily indacaterol/glycopyrrolate maintenance therapy.
Major finding: Indacaterol/glycopyrrolate improved measures of HRQoL component scores (symptoms [–7.3], activity [–3.6], and impacts [–5.0]), all P equal to or less than .001).
Study details: Secondary analysis of two phase 3, 12-week, randomized, placebo, active-controlled trials of twice-daily indacaterol/glycopyrrolate in 2,038 patients.
Disclosures: Sunovion Pharmaceuticals funded the study. The study authors report various disclosures.
Mahler DA el al. Chronic Obstr Pulm Dis. 2019;6(4).